中国医药：子公司获得药品补充申请批准

Core Viewpoint - China Medical's subsidiary, Sanyo Pharmaceutical, has received approval for a supplemental application for Carboprost injection, which is used in cesarean sections to prevent uterine atony and postpartum hemorrhage [1] Group 1: Approval and Product Details - Sanyo Pharmaceutical has been granted a "Drug Supplement Application Approval Notice" by the National Medical Products Administration for Carboprost injection [1] - The drug is intended for use in selective epidural or spinal anesthesia cesarean sections [1] - The approval allows for a change in the marketing authorization holder to Sanyo Pharmaceutical, while the drug approval number remains unchanged [1] Group 2: Financial and Market Impact - Sanyo Pharmaceutical has invested approximately 3.93 million yuan in this drug project [1] - The projected domestic sales for this drug in 2024 are estimated to be around 201 million yuan [1] - Becoming the marketing authorization holder for this drug enhances the company's product line and is expected to improve its market competitiveness [1]